These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Epigenetic inhibitors and their role in cancer therapy. Abdelaziz N; Therachiyil L; Sadida HQ; Ali AM; Khan OS; Singh M; Khan AQ; Akil ASA; Bhat AA; Uddin S Int Rev Cell Mol Biol; 2023; 380():211-251. PubMed ID: 37657859 [TBL] [Abstract][Full Text] [Related]
4. Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications. Silverman BR; Shi J Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999365 [TBL] [Abstract][Full Text] [Related]
5. Epigenetic mechanisms in gastric cancer. Gigek CO; Chen ES; Calcagno DQ; Wisnieski F; Burbano RR; Smith MA Epigenomics; 2012 Jun; 4(3):279-94. PubMed ID: 22690664 [TBL] [Abstract][Full Text] [Related]
6. Interplay between different epigenetic modifications and mechanisms. Murr R Adv Genet; 2010; 70():101-41. PubMed ID: 20920747 [TBL] [Abstract][Full Text] [Related]
7. Epigenetic modifications in gastric cancer: Focus on DNA methylation. Ebrahimi V; Soleimanian A; Ebrahimi T; Azargun R; Yazdani P; Eyvazi S; Tarhriz V Gene; 2020 Jun; 742():144577. PubMed ID: 32171825 [TBL] [Abstract][Full Text] [Related]
8. DNA methylation and chromatin modifiers in colorectal cancer. Vymetalkova V; Vodicka P; Vodenkova S; Alonso S; Schneider-Stock R Mol Aspects Med; 2019 Oct; 69():73-92. PubMed ID: 31028771 [TBL] [Abstract][Full Text] [Related]
9. Cancer epigenetics: from mechanism to therapy. Dawson MA; Kouzarides T Cell; 2012 Jul; 150(1):12-27. PubMed ID: 22770212 [TBL] [Abstract][Full Text] [Related]
10. Involvement of noncoding RNAs in epigenetic modifications of esophageal cancer. Xiao Y; Su M; Ou W; Wang H; Tian B; Ma J; Tang J; Wu J; Wu Z; Wang W; Zhou Y Biomed Pharmacother; 2019 Sep; 117():109192. PubMed ID: 31387188 [TBL] [Abstract][Full Text] [Related]
12. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets. Herranz M; Esteller M Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706 [TBL] [Abstract][Full Text] [Related]
13. The epigenomics of sarcoma. Nacev BA; Jones KB; Intlekofer AM; Yu JSE; Allis CD; Tap WD; Ladanyi M; Nielsen TO Nat Rev Cancer; 2020 Oct; 20(10):608-623. PubMed ID: 32782366 [TBL] [Abstract][Full Text] [Related]
15. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Timp W; Feinberg AP Nat Rev Cancer; 2013 Jul; 13(7):497-510. PubMed ID: 23760024 [TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Ramakrishnan S; Pili R Cancer J; 2013; 19(4):333-40. PubMed ID: 23867515 [TBL] [Abstract][Full Text] [Related]
17. Histone modification: cause or cog? Henikoff S; Shilatifard A Trends Genet; 2011 Oct; 27(10):389-96. PubMed ID: 21764166 [TBL] [Abstract][Full Text] [Related]
19. On the role of retinoblastoma family proteins in the establishment and maintenance of the epigenetic landscape. Fiorentino FP; Marchesi I; Giordano A J Cell Physiol; 2013 Feb; 228(2):276-84. PubMed ID: 22718354 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic changes in cancer. Iacobuzio-Donahue CA Annu Rev Pathol; 2009; 4():229-49. PubMed ID: 18840073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]